Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Catherine Saint-Laurent ThibaultDivya MoorjaneyMichael L GanzBruce SillShalini HedeYong YuanBoris GorshPublished in: Journal of medical economics (2017)